BeiLi Chemicals (Zhangjiagang) Co., Ltd.
 |
| Place of Origin: | China |
| Brand Name: | BeiLi |
| Certification: | ISO 9001:2008 |
| Model Number: | MBN.99P.N |
| Minimum Order Quantity: | unlimited |
|---|---|
| Price: | negotiation |
| Packaging Details: | plastic drum/carton drum/bag/ |
| Delivery Time: | 3-10 working days |
| Payment Terms: | negotiation |
| Synonym: | M-Anisonitrile; AKOS B004087; 3-ANISONITRILE; 3-METHOXYBENZONITRILE; | CAS No: | 1527-89-5 |
|---|---|---|---|
| Molar Mass (g/mol): | 133.15 | Reach PR#: | 05-2119085533-37-0000 |
| Grade: | Pharmaceutical Grade | Density: | 1.089 G/mL At 25 °C |
| P/N#: | MBN.99P.N | Melting Point: | 11.0~112.0ºC(13mmHg) |
| High Light: | pharmaceutical raw chemical,pharmaceutical active ingredients |
||
3-methoxybenzontrile CAS 1527-89-5 as pharmaceutical raw materials
3-Methoxybenzonitrile, also known as 3-methoxy benzonitrile, m-methoxy benzonitrile, colorless or slightly yellow liquid.
CAS No: 1527-89-5
EC No: 216-201-3
Packaging:200kgs/iron drum with plastic lining
Chemical Product and Company Identification
Name: 3-Methoxybenzonitrile, 99%
Synonyms: m-Anisonitrile; AKOS B004087; 3-ANISONITRILE; 3-METHOXYBENZONITRILE
Company Identification: Beili Chemicals (Zhangjiagang) Co., Ltd.
Composition, Information on Ingredients
Substance: 3-Methoxybenzonitrile
% content: 99+
CAS Number: 1527-89-5
EINECS: 216-201-3
Hazard Symbols: XN
Hazards Identification
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
The toxicological properties of this material have not been investigated. Use appropriate procedures to prevent opportunities for direct contact with the skin or eyes and to prevent inhalation.
Specifications
| P/N# | MBN.99P.N | Grade | Pharmaceutical grade |
| Purity | ≥99.0% | Melting range | |
| Water | Quality standard | meets company specification |
Application
Used as a pharmaceutical intermediate, it is an important intermediate of the new antipyretic analgesic - tapentadol. The drug is mainly used to relieve moderate and severe acute pain, especially for the relief of adults over 18 years of age. Its quick release tablets were approved by the US Food and Drug Administration (trade name: NUCNTA) in November 2008 to relieve moderate and severe acute pain;Its sustained-release tablets were approved for marketing in August 2012 (trade name: NUCYNTA ER) for the treatment of adult diabetic neuropathy (DPN) -related neuropathic pain.In addition, it also can participate in a variety of organic synthesis.
Storage condition
Store in a cool, dry place, avoid direct sunlight. Store in a tightly closed container.
Exposure Controls, Personal Protection
Engineering Controls: Use adequate general or local exhaust ventilation to keep airborne concentrations below the permissible exposure limits.
Personal Protective Equipment
Eyes: Wear safety glasses and chemical goggles if splashing is possible.
Skin: Wear appropriate protective gloves and clothing to prevent skin exposure.
Clothing: Not available.
Contact Person: lick
